Egetis Therapeutics
EGTX | XSTO
Overview
Corporate Details
- ISIN(s):
- SE0003815604
- LEI:
- 549300RZCKGWRUBPMY22
- Country:
- Sweden
- Address:
- Klara Norra Kyrkogata 26, 111 22 Stockholm
- Website:
- https://www.egetis.com/
- Sector:
- Health Care
- Industry:
- Pharmaceuticals
Description
Egetis Therapeutics is an innovative and integrated pharmaceutical company, focusing on projects in late-stage development for commercialization for treatments of serious diseases with significant unmet medical needs in the orphan drug segment. The Company’s lead candidate Emcitate is under development for the treatment of patients with monocarboxylate transporter 8 (MCT8) deficiency, a highly debilitating rare disease with no available treatment. In previous studies (Triac Trial I and a long-term real-life study) Emcitate has shown highly significant and clinically relevant results on serum T3 levels and secondary clinical endpoints. As a result of fruitful regulatory interaction Egetis intends to submit a marketing authorisation application (MAA) for Emcitate to the European Medicines Agency (EMA) in the first half of 2023 based on existing clinical data.
Financials & KPIs
No Financial Data Available
Standardized financial statements for the selected period are not yet available.
Filings
| Date | Filing | Language | Size | Actions |
|---|---|---|---|---|
| 2025-05-16 00:00 |
Annual Report
|
Swedish | 12.4 MB | |
| 2025-05-06 17:59 |
Regulatory News Service
Kommuniké från Egetis Therapeutics årsstämma 2025
|
Swedish | 55.3 KB | |
| 2025-05-06 17:59 |
Regulatory News Service
Bulletin from Egetis Therapeutics’ Annual General Meeting 2025
|
English | 52.3 KB | |
| 2025-04-30 07:00 |
Quarterly Report
|
Swedish | 3.7 MB | |
| 2025-04-30 07:00 |
Quarterly Report
|
English | 3.3 MB | |
| 2025-02-26 07:00 |
Earnings Release
|
Swedish | 735.2 KB | |
| 2025-02-26 07:00 |
Annual Report
|
English | 764.5 KB | |
| 2025-02-13 15:25 |
Regulatory News Service
European Commission approves Egetis’ Emcitate® (tiratricol) as the first and on…
|
English | 73.3 KB | |
| 2025-02-13 15:25 |
Regulatory News Service
EU-kommissionen godkänner Egetis Emcitate® (tiratricol) som den första och enda…
|
Swedish | 74.4 KB | |
| 2024-12-30 16:42 |
Declaration of Voting Results & Voting Rights Announcements
Change in the number of shares and votes in Egetis Therapeutics
|
English | 59.0 KB | |
| 2024-12-30 16:42 |
Declaration of Voting Results & Voting Rights Announcements
Ändring av antalet aktier och röster i Egetis Therapeutics
|
Swedish | 65.1 KB | |
| 2024-12-16 17:20 |
Transaction in Own Shares
Emission och återköp av C-aktier för incitamentsprogram
|
Swedish | 54.5 KB | |
| 2024-12-16 17:20 |
Regulatory News Service
Issuance and repurchase of class C shares for incentive programs
|
English | 46.2 KB | |
| 2024-12-12 15:43 |
Regulatory News Service
Egetis receives positive CHMP opinion for Emcitate® (tiratricol) for the treatm…
|
English | 74.7 KB | |
| 2024-12-12 15:43 |
Regulatory News Service
Egetis erhåller positivt CHMP-utlåtande för Emcitate® (tiratricol) för behandli…
|
Swedish | 75.4 KB |
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| 2023-06-05 | Elisabeth Svanberg | Other | Buy | 10,280 | 54,586.80 SEK |
| 2023-06-01 | Kristina Sjöblom Nygren | Other | Buy | 5,000 | 24,650.00 SEK |
| 2023-05-31 | Mats Blom | Other | Buy | 200,000 | 991,600.00 SEK |
| 2022-06-20 | Henrik Krook | Other | Buy | 84,999 | 281,176.69 SEK |
| 2022-06-20 | Henrik Krook | Other | Sell | 84,999 | 274,291.77 SEK |
| 2022-05-17 | PharmaExec Consulting AB | Other | Other | 68,493 | 249,999.45 SEK |
| 2022-05-17 | Per Thomas Lönngren | Other | Other | 49,536 | 180,806.40 SEK |
| 2022-05-13 | Henrik Krook | Other | Buy | 283,330 | N/A |
| 2021-11-24 | Per Thomas Lönngren | Other | Buy | 65,000 | 396,500.00 SEK |
| 2021-11-23 | Per Thomas Lönngren | Other | Buy | 129 | 764.97 SEK |
Peer Companies
| Company | Country | Ticker | View | |
|---|---|---|---|---|
|
ABIVAX | France | ABVX | |
|
Addex Therapeutics Ltd | Switzerland | ADXN | |
|
AegirBio AB | Sweden | AEGIR | |
|
AGRONOMICS LIMITED | Isle of Man | ANIC | |
|
AIREA PLC | United Kingdom | AIEA | |
|
Alkaloid AD | North Macedonia | ALK | |
| Alma Yesodot Ltd. | Israel | KVSR | ||
|
Antibiotice S.A. | Romania | ATB | |
|
Aran Research & Development (1982) Ltd. | Israel | ARAN | |
|
Asarina Pharma AB | Sweden | ASAP |